Biological and Clinical Database for Pancreatic Adenocarcinoma
Biological and Clinical Database for Pancreatic Adenocarcinoma
BACAP is a biobank dedicated to the pancreatic adenocarcinoma funded by institut national
 institue du cancer (INCa) and coordinated by Dr Barbara Bournet from Toulouse hospital. This
 base includes clinical data and biological samples such as blood, serum, plasma, saliva, DNA
 and RNA from tumors cells.

 The mission of this prospective project is to make available to the scientific community a
 clinical biological base from patients with pancreatic adenocarcinoma
Pancreatic cancer represents the fifth cause of death by cancer in Western countries. In over
 90% of cases, it is due to an adenocarcinoma. The only curative treatment for pancreatic
 cancer remains the surgical exeresis. This one can only be suggested as a curative treatment
 in only 10 to 15% of cases. Besides, prevention or screening is impossible due to the absence
 of clearly identified risk factors or groups and to the absence of useful markers for the
 diagnosis in clinical practice.

 The research efforts in this area must face a double challenge: saving time while improving
 the diagnosis period and strengthen the therapeutic equipment. It is important to identify
 and characterise the new molecular markers applicable for a better diagnosis and/or treatment
 (especially the response factors to chemotherapy). The present project aims at creating a
 multicentre national network used to set up a clinical biological base (CBB) dedicated to the
 pancreatic adenocarcinoma, built on the best quality standards, for the biological resources
 as well as the associated clinical and epidemiological data.

 The originality of this CBB relies on the fact that it will have not only tumour tissues
 sampled from surgical specimens of resectable tumours but also cell and biopsy material from
 unresectable and/or metastatic tumours sampled under endoscopic ultrasonography (1500
 biopsies over 3 years coupled to systematic blood samples). Endoscopic ultrasonography is a
 technique used to specifically perform biopsies on pancreatic tumours and to obtain useful
 cell material for research. To these samples will be associated every clinical and
 epidemiological target data required for research projects related to this unique CBB in
 France. From these samples, DNA and RNA will be especially isolated, as it is a precious
 biological material for the programmed molecular analyses.

 There are many stakes: creating a French network in order to form, with the prospective plans
 over 3 years, a collection of tissue, biopsies, nucleic acids from pancreatic cancer
 associated to circulating blood samples and relevant clinical data. Thanks to this
 collection, the investigator team hope to be able to identify new molecular markers (from
 cancer tissue and/or circulating blood from pancreatic cancer patients) applicable to
 clinical practice to diagnose, to assess the prognosis or to predict the response to
 pancreatic cancer chemotherapy. The investigator team will also try to identify new risk
 factors for this cancer, especially regarding the diet. The base will thus be made up from 12
 different French centres from University Hospital and private Centres where
 gastroenterologists, oncologists, digestive surgeons, anatomopathologists, epidemiologists
 intervene as they are all associated to scientific teams dedicated to pancreatic cancer,
 itself already formed in collaborative networks.

 Investigators hope through this project: to get a unique and exceptional CBB for pancreatic
 cancer, to reach the required standards (especially Inca) for this CBB, and to be
 internationally recognised. This base will be a strong guarantee to identify new molecular
 markers for the diagnosis, the prognosis, and the predictive response to chemotherapy for
 pancreatic cancer, especially when locally advanced. Finally, the epidemiological projects
 related to this project are originally about the nutritional issues (regardless of the lipid
 diet and the cachexia) associated to pancreatic cancer.
Inclusion Criteria:

 -  Patient eighteen years old

 -  Histologically or cytologically confirmed pancreatic adenocarcinoma

 -  Solid pancreatic mass explored with tomodensitometry or endoscopic ultrasonography
 fine-needle aspiration

 -  Informed consent signed

 Exclusion Criteria:

 -  no informed consent

 -  pregnancy women

 -  no histologically or cytologically confirmed pancreatic adenocarcinoma